复方中药治疗慢性病毒性肝炎肝纤维化的Meta分析

A systematic review of traditional Chinese medicine for liver fibrosis of chronic hepatitis virus

目的:对中药方剂治疗慢性病毒性肝炎肝纤维化的有效性进行评价。方法:检索35年内文献(截止2011年)。将复方中药与对照组(抗病毒或保肝药)的随机临床试验纳入本研究。制定文献纳入标准和文献排除标准。采用Cochrane系统评价员手册和Jadad质量记分法对文献进行质量评价。分析指标为计数资料,用相对危险度(RR)及其95%可信区间(95%C I)表示。结果:共纳入5个临床随机对照试验。慢性病毒性肝炎肝纤维化或代偿期肝硬化共计359例。复方中药在改善肝纤维化与对照组比较合并效应量RR=2.03,95%C I(1.52,2.72),P<0.00001。无不良反应。结论:复方中药有明显的改善肝纤维化(S分期)作用,未见不良反应的报道。

Objective：To value the availability of traditional chinese medicine for liver fibrosis of chronic hepatitis virus.Methods：To search 35 years of literature up to January 2011.Randomized clinical trials on the treatment group with compound chinese medicine compared with control group（antivirus or prevention liver medicine） were enrolled in this study.To formulated the standard of inclusion and exclusion.Two evaluator document the randomized clinical trials by Cochrane system′s the quality evaluation manual and Jadad quality scores independently.Relative ratio（RR） and 95% confidence interval（95%CI） for counting material was elected.Rusults：Five clinical randomized clinical trials were included,involving 359 cases of liver fibrosis with chronic and compensatory viral hepatitis.Compound chinese medicine in the improvement of liver fibrosis compared with controls was statistically different significance（total RR=2.03,95% CI（1.52,2.72）.Five randomized clinical trials didn′t reported adverse effects.Conclusion：Compound Chinese medicine can significantly improve staging liver fibrosis in S stages.No adverse was reported.